|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Neurological events with tumour necrosis factor alpha inhibitors reported to the Food and Drug Administration Adverse Event Reporting System显示文摘 | P. Deepak D. J. Stobaugh M. Sherid H. Sifuentes E. D. Ehrenpreis | 2013 | Aliment Pharmacol Ther2013，，4： | 2 |
| 2 | T - cell non - Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor - alpha ( TNF - alpha) inhibitors : results of the REFURBISH study 显示文摘 | Deepak P Sifuentes H Sherid M | 2013 | AmJGastroenterol2013，108，1： | 1 |
| 3 | Lubiprostone induced ischemic colitis显示文摘Ischemic colitis accounts for 6%-18% of the causes of acute lower gastrointestinal bleeding.It is often multifactorial and more commonly encountered in the elderly.Several medications have been implicated in the development of colonic ischemia.We report a case of a 54-year old woman who presented with a two-hour history of nausea,vomiting,abdominal pain,and bloody stool.The patient had recently used lubiprostone with close temporal relationship between the increase in the dose and her symptoms of rectal bleeding.The radiologic,colonoscopic and histopathologic findings were all consistent with ischemic colitis.Her condition improved without any serious complications after the cessation of lubiprostone.This is the first reported case of ischemic colitis with a clear relationship with lubiprostone(Naranjo score of 10).Clinical vigilance for ischemic colitis is recommended for patients receiving lubiprostone who are presenting with abdominal pain and rectal bleeding. | Muhammed Sherid Humberto Sifuentes Salih Samo Parakkal Deepak Subbaramiah Sridhar | 2013 | World Journal of Gastroenterology2013，19，2： | 1 |
| 4 | T-cell non-Hodgkin'slymphomas reported to the FDA AERS with tumor necrosisfactor-alpha (TNF-α) inhibitors: results of the REFURBISH study显示文摘 | Deepak P Sifuentes H Sherid M | 2013 | Am J Gastroenterol2013，108，1： | 1 |
| 5 | Lubiproston induced isehemic co- litis显示文摘 | Sherid M Sifuentes H Samo S et at | 2013 | World J Gastmentem12013，19，2： | 1 |
| 6 | What's new about inflammatory bowel diseases in Ischemic colitis induced by the newly reformulated multicomponent weight-loss supplement Hydroxycut(?)显示文摘 | Sherid M Samo S Sulaiman S | 2013 | World J Gastrointest Endosc2013，5，4： | 1 |
| 7 | Ischemic colitis induced by the newly reformulated multicomponent weight-loss supplement Hydroxycut~显示文摘Ischemic colitis accounts for 6%-18% of causes of acute lower gastrointestinal bleeding. It is more often multifactorial and more common in elderly. Drugs are considered important causative agents of this disease with different mechanisms. In this paper, we describe a 37-year-old otherwise healthy female presented with sudden onset diffuse abdominal pain and bloody stool. Radiologic, colonoscopic and histopathologic findings were all consistent with ischemic colitis. Her only suspected factor was hydroxycut which she had been taking for a period of 1 mo prior to her presentation. Her condition improved uneventfully after cessation of hydroxycut, bowel rest, intravenous hydration, and antibiotics. This is a first case of ischemic colitis with clear relationship with hydroxycut use (Naranjo score of 7). Our case demonstrates the importance of questioning patients regarding the usage of dietary supplements; especially since many patients consider them safe anddo not disclose their use voluntarily to their physicians. Hydroxycut has to be considered as a potential trigger for otherwise unexplained ischemic colitis. | Muhammed Sherid Salih Samo Samian Sulaiman Joseph H Gaziano | 2013 | World Journal of Gastrointestinal Endoscopy2013，5，4： | 1 |
| 8 | Types of Colitis Based on Histology显示文摘 | Muhammed Sherid Eli D. Ehrenpreis | 2011 | Disease-a-Month2011，，9： | 1 |
| 9 | Types of colitis based on histology显示文摘 | Sherid M Ehrenpreis ED | 2011 | Dis Mon2011，57，9： | 1 |
| 10 | Risk factors of re- current ischemic colitis: a multicenter retrospective study 显示文摘 | Sherid M Sifuentes H Samo S | 2014 | Korean J Gastroenterol2014，63，5： | 1 |
| 11 | Risk of gastrointestinal bleeding with dabigatran: a head-to-head comparative study with fivaroxaban 显示文摘 | Sherid M Sifuentes H Sulaiman S | 2014 | Digestion2014，90，2： | 1 |
| 12 | Klippel-Trenaunay syndrome causing life-threatening GI bleeding:a case report and review of the literature显示文摘 | Samo S Sherid M Husein H | 2013 | Case Rep Gastrointest Med2013，2013，81： | 1 |
| 13 | T-cell non-Hodgkin' s lym- phomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-ct) inhibitors: results of the REFURBISH study 显示文摘 | Deepak P Sifuentes H Sherid M | 2013 | Am J Gastroenterol2013，108，1： | 1 |
| 14 | Risk of gastrointestinal bleeding with dabigatran:a head-to-head comparative study with rivaroxaban显示文摘 | SHERID M SIFUENTES H SULAIMAN S | 2014 | Digestion2014，90，2： | 1 |
| 15 | 放疗引起的主动脉食管瘘:病例报告和文献复习显示文摘Aortoesophageal fistula(AEF)is a rare cause of massive upper gastrointestinal hemorrhage.Thoracic aortic aneurysm,esophageal foreign body,esophageal cancer and post-surgical complications are common causes of AEF;however,AEF induced by radiation therapy is a rare phenomenon and seldom described in the literature.It is a catastrophic condition which requires rapid implementation of resuscitative measures,broad-spectrum antibiotics and surgical or endovascular intervention.Transthoracic endovascular aortic repair(TEVAR)is a newer and less invasive technique,which helps to achieve rapid hemostasis in patients with severe hemodynamic instability and offers advantages over conventional repair of the aorta in emergency situations.However initial TEVAR should be followed up with a more definitive surgical repair of the aorta and the esophagus,to lower the mortality rate and achieve better outcomes.We describe here a case of a seventyyear-old male who presented with massive upper gastrointestinal bleeding due to AEF induced by radiation therapy,and his subsequent successful initial management with TEVAR. | Malav P.Parikh Muhammed Sherid Sreelakshmi Panginikkod Harsh A.Rawal Venu Gopalakrishnan | 2016 | Gastroenterology Report2016，4，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员